Skip to main content
SSY Group Limited logo

SSY Group Limited — Investor Relations & Filings

Ticker · 2005 ISIN · KYG8406X1034 HKEX Manufacturing
Open in API
Filings indexed 1,213 across all filing types
Latest filing 2023-11-01 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2005

About SSY Group Limited

http://www.ssygroup.com.hk

SSY Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of pharmaceutical products. The Group is a prominent manufacturer, with a core focus on producing a wide range of intravenous infusion solutions and finished drugs. Complementing its pharmaceutical offerings, the company also manufactures essential packaging materials, including non-PVC soft bags and PP plastic containers. SSY Group supplies its comprehensive product line, which often utilizes green production technologies aimed at reducing costs and power consumption, primarily to hospitals and medical institutions.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return on movements in securities for SSY Group Limited, specifically covering authorized and issued share capital, share options, and confirmations related to share issuance. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content focuses on share capital changes and confirmations rather than financial performance, management changes, or earnings. It is a regulatory submission related to share capital movements and confirmations, not a full financial report or announcement of voting results. Given the detailed nature and regulatory context, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-11-01 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors regarding recent approvals for drug production and registration from the National Medical Products Administration of China. It is an update on product development and does not contain financial statements, earnings data, or regulatory filings related to financial performance. The document is relatively short (2028 characters) and serves to inform shareholders and investors about business progress rather than reporting financial results or governance changes. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or regulatory filing. It is also not a report publication announcement since it contains substantive content about product approvals. Therefore, the best fitting category is a general Regulatory Filing (RNS) as a voluntary business update announcement that does not fit other specific categories.
2023-10-31 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from the board of directors regarding product development updates, specifically approvals from the National Medical Products Administration of China for generic drugs. It is not a financial report, earnings release, or regulatory filing related to financial performance or governance changes. The document is short (1994 characters) and serves to inform shareholders and investors about business developments rather than detailed financial data or formal filings. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous update that does not fit other specific categories, which corresponds to Regulatory Filings (RNS).
2023-10-30 English
UNAUDITED OPERATING RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
Interim / Quarterly Report Classification · 95% confidence The document is an announcement of unaudited operating results for the nine months ended 30 September 2023. It explicitly states that the financial information is unaudited and based on management accounts, and it cautions that this information should not be regarded as audited financial results. The document provides detailed financial data and analysis for a period shorter than a full fiscal year (nine months), which fits the definition of an Interim / Quarterly Report (IR). It is not a full annual report (10-K), nor is it merely an announcement of a report publication (RPA). The presence of substantive financial data and analysis confirms it is a financial report type. Therefore, the correct classification is Interim / Quarterly Report (IR). 9M 2023
2023-10-27 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings
2023-10-26 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from the board of directors regarding an update on product development, specifically about a supplemental application for a drug clinical trial and its approval. It is not a financial report, earnings release, or regulatory filing related to financial performance. The document is relatively short (2314 characters) and serves to inform shareholders and investors about business developments rather than financial results or governance changes. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing or certification. The content is clearly an announcement about business progress, which aligns best with the Regulatory Filings (RNS) category as a general announcement that does not fit other specific categories.
2023-10-24 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.